Nemluvio is now the first approved monoclonal antibody that specifically targets interleukin-31 receptor alpha ...

The medication, also approved in the United States, is the first approved monoclonal antibody that specifically blocks the signaling of interleukin (IL)-31.

Swiss dermatology company Galderma has announced two European approvals for Nemluvio (nemolizumab) to treat both atopic ...

Galderma today announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency and Swissmedi ...

Galderma's efforts to expand the market for Nemluvio are bearing more fruit ... In addition, the drug scored an endorsement to treat prurigo nodularis in adults. In the late-stage Arcadia and ...

A new medicine, Nenolizumab, has been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) to treat two ...

Dupilumab, an interleukin-4 receptor antagonist, is expected to decrease the type 2 inflammation seen in bullous pemphigoid.

Sanofi SNY and partner Regeneron REGN announced that the FDA has accepted their supplemental biologics license application ...